Merck Message Board - Msg: 22254935

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck

MRK 100.72

+1.5%

Dec 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: William F. Wager, Jr.	3/13/2006 11:27:02 AM
	of 1580

Merck Says Vytorin Does Well in Studies... By TSC Staff 3/13/2006 7:50 AM EST Merck presented data Monday showing its Vytorin cholesterol treatment performing well in several studies. Merck released a new analysis of three studies that it says shows Vytorin reduced LDL, or "bad," cholesterol by an average of 52.5% in patients with high cholesterol. The company said the same analysis found its other cholesterol drug, Zocor, showed an average reduction of 38%. Merck's analysis pooled data from three similar randomized studies that included a total of 3,083 patients with primary hypercholesterolemia. The study also measured a risk factor for cardiovascular disease called "C-reactive protein," or CRP. A pooled analysis across all doses of Vytorin and Zocor found geometric mean CRP levels declined in patients taking Vytorin by 31% as compared to a 14.3% reduction in the group of patients taking Zocor. The results were presented Monday at the 55th Annual Scientific Session of the American College of Cardiology.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next